Laboratorios Farmaceuticos Rovi ( (ES:ROVI) ) has shared an announcement.
Laboratorios Farmacéuticos ROVI, S.A. has been granted a subsidy of 36.3 million euros from the Center for Technological Development and Innovation (CDTI) for its R&D project, LAISOLID, under the IPCEI Med4Cure initiative. This funding will support the development of new aseptic filling technologies and methodologies to accelerate drug development, with potential applications in tissue regeneration and long-acting injectable formulations, enhancing ROVI’s position in cutting-edge health solutions.
More about Laboratorios Farmaceuticos Rovi
Laboratorios Farmacéuticos ROVI, S.A. operates in the pharmaceutical industry, focusing on the development and manufacturing of prolonged-release drugs and aseptic filling technologies. The company is involved in innovative research and development projects, particularly in the field of regenerative medicine and long-acting injectable formulations.
Average Trading Volume: 131,908
Technical Sentiment Signal: Sell
Current Market Cap: €2.63B
Find detailed analytics on ROVI stock on TipRanks’ Stock Analysis page.